TICKERNERD
Menu
CODXCODXHealthcare · Medical Devices

CODX Stock Forecast: Co-Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$1.52
+7.04% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 8 Aug 2026 — in the lower half.

Market cap
$5.6M
Ticker Nerd rank
29 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
+5.6%
1M
−43.9%
YTD
−70.0%
1Y
−79.5%
From 52W high
−96.0%
From 52W low
+18.3%
$1
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CODX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Co-Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Accruals
94
Size
92
Momentum
28
Revisions
25
Issuance
18
Value
11
Quality
10
Volatility
9

Growth (98): Sales and profits are climbing, and climbing faster than before.

Volatility (9): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Co-Diagnostics, Inc. — and when they’d sell — is the membership.

Wall Street

CODX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CODX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Oct 25Jan 26Apr 26Jul 26CODX

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Jan 2026Maxim GroupDowngradeHold—
26 Nov 2025Maxim GroupInitiatesBuy—
24 Nov 2025HC Wainwright & Co.ReiteratesNeutral—
28 Oct 2025D. Boral CapitalMaintainsBuy—
16 Oct 2025D. Boral CapitalMaintainsBuy—
19 Sept 2025D. Boral CapitalMaintainsBuy—
17 Sept 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
28 Apr 2025D. Boral CapitalInitiatesBuy—
28 Mar 2025HC Wainwright & Co.MaintainsNeutral—
11 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
12 Aug 2024HC Wainwright & Co.MaintainsNeutral—
17 June 2024HC Wainwright & Co.ReiteratesNeutral—
13 May 2024HC Wainwright & Co.MaintainsNeutral—
15 Mar 2024HC Wainwright & Co.MaintainsNeutral—
29 Dec 2023HC Wainwright & Co.ReiteratesNeutral—
13 Nov 2023HC Wainwright & Co.MaintainsNeutral—
14 Aug 2023HC Wainwright & Co.MaintainsNeutral—
15 May 2023HC Wainwright & Co.ReiteratesNeutral—
20 Mar 2023HC Wainwright & Co.DowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CODX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Co-Diagnostics, Inc. (CODX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
7.8×

Cheaper than 17% of US stocks

Price / book
0.3×

Cheaper than 87% of US stocks

EV / EBITDA
0.0×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
190.3%

Higher than 96% of US stocks

Earnings growth (YoY)
190.3%

Higher than 90% of US stocks

Gross margin
−32.8%

Higher than 3% of US stocks

Operating margin
−6309.1%

Higher than 3% of US stocks

Net margin
64.3%

Higher than 97% of US stocks

Returns & dividend
Return on equity
−151.7%

Higher than 9% of US stocks

Return on assets
−52.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CODX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CODXCo-Diagnostics, Inc.$5.6M
29
SINTSINTX Technologies, Inc.$10.6M
25
AMIXAutonomix Medical, Inc.$9.7M
12
VNRXVolitionRX Ltd.$9.3M
26
ICCMIceCure Medical Ltd.$8.6M
36
MODDModular Medical, Inc.$13.2M
11
NMTCNeuroOne Medical Technologies Corp.$13.8M
24
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CODX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CODX news & analysis

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

PRNewsWire · 6 Aug 2026positive

Co-Diagnostics announced it submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by Application, to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument for point-of-care use. The submission follows the previously announced completion of the clinical and analytical performance studies supporting the test.

Why it matters — This regulatory submission moves Co-Diagnostics' point-of-care respiratory multiplex test a step closer to potential FDA clearance, which could expand its product portfolio into decentralized testing settings.

Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast

PRNewsWire · 30 July 2026neutral

Co-Diagnostics announced it will release its second quarter 2026 financial results on August 13, 2026, after market close, and will host a conference call and webcast the same day at 4:30 p.m.

Why it matters — The announcement provides the date and time for CODX's quarterly earnings release and investor webcast, which shareholders and analysts will watch for updates on the company's financial performance.

Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies

PRNewsWire · 28 July 2026positive

Co-Diagnostics announced that its joint venture CoSara has sent SARAGENE® Bundibugyo Virus Test kits to a third-party lab for evaluation at the request of the India Centre for Cellular and Molecular Platforms (C-CAMP). The company also completed proof of concept for its first blood-borne Ebola test on the Co-Dx PCR Pro instrument.

Why it matters — A CODX watcher would care because the company is advancing its Ebola testing capabilities and engaging with an Indian government-backed research initiative, potentially opening new diagnostic applications and partnerships.

FAQ

Frequently asked questions about CODX stock

Is CODX stock a buy right now?

Of the 1 analysts covering Co-Diagnostics, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Co-Diagnostics, Inc. 29 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CODX?

As at 8 Aug 2026, Co-Diagnostics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

What is the CODX stock forecast for 2030?

No analyst covering Co-Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CODX are extrapolating price history, which says nothing about the business.

How has CODX stock performed over the past year?

Co-Diagnostics, Inc. returned -79.5% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Co-Diagnostics, Inc. do?

Co-Diagnostics Inc. is a molecular diagnostics company that develops, manufactures, and sells reagents for diagnostic tests relying on the detection and analysis of nucleic acid molecules.

What is the latest news on CODX?

The most recent item we track (PRNewsWire, 6 Aug 2026): "Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test". Co-Diagnostics announced it submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by Application, to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument for point-of-care use. The submission follows the previously announced completion of the clinical and analytical performance studies supporting the test.

Company

About Co-Diagnostics, Inc.

Co-Diagnostics Inc. is a molecular diagnostics company that develops, manufactures, and sells reagents for diagnostic tests relying on the detection and analysis of nucleic acid molecules. It operates in the United States and internationally, focusing on polymerase chain reaction (PCR) technologies for point-of-care and at-home testing. The company's Co-Dx PCR platform enables rapid molecular testing, supporting diagnostics for infectious diseases including COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and Zika virus. Co-Diagnostics Inc. also advances tools for liquid biopsy in cancer screening and agricultural applications, automating complex procedures to deliver low-cost, efficient solutions. Through its joint venture CoSara Diagnostics Pvt. Ltd. in India, it pursues decentralized PCR testing, including proprietary sample preparation instruments for primary health centers. Founded in 2013 and headquartered in Salt Lake City, Utah, Co-Diagnostics Inc. plays a key role in accessible molecular diagnostics across healthcare, oncology, and agriculture sectors.

CEO Mr. Dwight H. Egan · 115 employees · United States · https://co-dx.com